Ouro Fino Saúde Animal Participações Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Ouro Fino Saúde Animal Participações.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 19.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Getting In Cheap On Ouro Fino Saúde Animal Participações S.A. (BVMF:OFSA3) Is Unlikely
Dec 19
We Think Ouro Fino Saúde Animal Participações' (BVMF:OFSA3) Healthy Earnings Might Be Conservative
Aug 15One Ouro Fino Saúde Animal Participações S.A. (BVMF:OFSA3) Analyst Just Cut Their EPS Forecasts
May 19Is Ouro Fino Saúde Animal Participações (BVMF:OFSA3) A Risky Investment?
Dec 20These 4 Measures Indicate That Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Is Using Debt Reasonably Well
Jul 28We Think Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Can Stay On Top Of Its Debt
Feb 01Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Has A Pretty Healthy Balance Sheet
May 27Is Now The Time To Put Ouro Fino Saúde Animal Participações (BVMF:OFSA3) On Your Watchlist?
Mar 01Does Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Have A Healthy Balance Sheet?
Feb 08Ouro Fino Saúde Animal Participações S.A.'s (BVMF:OFSA3) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 21Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Is Growing Earnings But Are They A Good Guide?
Jan 03
Introducing Ouro Fino Saúde Animal Participações (BVMF:OFSA3), A Stock That Climbed 42% In The Last Three Years
Dec 15Should You Be Adding Ouro Fino Saúde Animal Participações (BVMF:OFSA3) To Your Watchlist Today?
Nov 27What You Can Learn From Ouro Fino Saúde Animal Participações S.A.'s (BVMF:OFSA3) P/E
Aug 09We Think Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Is Taking Some Risk With Its Debt
Jul 13In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ouro Fino Saúde Animal Participações has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 959 | 91 | 19 | 65 | N/A |
| 6/30/2024 | 940 | 54 | 105 | 153 | N/A |
| 3/31/2024 | 954 | -34 | 127 | 176 | N/A |
| 12/31/2023 | 943 | -50 | 143 | 190 | N/A |
| 9/30/2023 | 985 | -23 | 187 | 236 | N/A |
| 6/30/2023 | 1,002 | 17 | 123 | 181 | N/A |
| 3/31/2023 | 1,006 | 111 | 106 | 166 | N/A |
| 12/31/2022 | 1,041 | 131 | 20 | 90 | N/A |
| 9/30/2022 | 989 | 122 | -39 | 32 | N/A |
| 6/30/2022 | 943 | 112 | -1 | 65 | N/A |
| 3/31/2022 | 939 | 120 | -33 | 34 | N/A |
| 12/31/2021 | 905 | 114 | -20 | 47 | N/A |
| 9/30/2021 | 855 | 108 | 20 | 68 | N/A |
| 6/30/2021 | 845 | 119 | 32 | 69 | N/A |
| 3/31/2021 | 787 | 101 | 61 | 92 | N/A |
| 12/31/2020 | 730 | 90 | 87 | 112 | N/A |
| 9/30/2020 | 706 | 83 | 76 | 112 | N/A |
| 6/30/2020 | 635 | 50 | 33 | 77 | N/A |
| 3/31/2020 | 640 | 50 | 12 | 60 | N/A |
| 12/31/2019 | 620 | 46 | 4 | 56 | N/A |
| 9/30/2019 | 598 | 40 | 28 | 75 | N/A |
| 6/30/2019 | 604 | 50 | 29 | 80 | N/A |
| 3/31/2019 | 588 | 60 | 3 | 58 | N/A |
| 12/31/2018 | 589 | 69 | -5 | 43 | N/A |
| 9/30/2018 | 576 | 72 | -3 | 43 | N/A |
| 6/30/2018 | 546 | 60 | N/A | 46 | N/A |
| 3/31/2018 | 522 | 49 | N/A | 79 | N/A |
| 12/31/2017 | 505 | 38 | N/A | 100 | N/A |
| 9/30/2017 | 442 | 3 | N/A | 91 | N/A |
| 6/30/2017 | 437 | 0 | N/A | 82 | N/A |
| 3/31/2017 | 434 | -9 | N/A | 61 | N/A |
| 12/31/2016 | 457 | -5 | N/A | 42 | N/A |
| 9/30/2016 | 523 | 31 | N/A | 27 | N/A |
| 6/30/2016 | 547 | 44 | N/A | 34 | N/A |
| 3/31/2016 | 545 | 58 | N/A | 17 | N/A |
| 12/31/2015 | 534 | 69 | N/A | 16 | N/A |
| 9/30/2015 | 580 | 61 | N/A | 17 | N/A |
| 6/30/2015 | 459 | 50 | N/A | 13 | N/A |
| 3/31/2015 | 414 | 46 | N/A | 20 | N/A |
| 12/31/2014 | 402 | 43 | N/A | 5 | N/A |
| 12/31/2013 | 384 | 54 | N/A | 33 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if OFSA3's forecast earnings growth is above the savings rate (10.4%).
Earnings vs Market: Insufficient data to determine if OFSA3's earnings are forecast to grow faster than the BR market
High Growth Earnings: Insufficient data to determine if OFSA3's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if OFSA3's revenue is forecast to grow faster than the BR market.
High Growth Revenue: Insufficient data to determine if OFSA3's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OFSA3's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:09 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ouro Fino Saúde Animal Participações S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|